35,526 Bio-Rad Laboratories, Inc. $BIO Shares Sold by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. reduced its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 49.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 36,051 shares of the medical research company’s stock after selling 35,526 shares during the quarter. Mawer Investment Management Ltd.’s holdings in Bio-Rad Laboratories were worth $13,617,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP boosted its stake in Bio-Rad Laboratories by 1.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,089,323 shares of the medical research company’s stock worth $303,637,000 after buying an additional 12,251 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in Bio-Rad Laboratories by 57.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock valued at $68,478,000 after buying an additional 85,393 shares during the period. Hosking Partners LLP grew its holdings in Bio-Rad Laboratories by 1.1% in the 3rd quarter. Hosking Partners LLP now owns 95,472 shares of the medical research company’s stock valued at $36,061,000 after buying an additional 1,042 shares during the period. Hound Partners LLC increased its stake in shares of Bio-Rad Laboratories by 125.9% during the 1st quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock valued at $27,241,000 after acquiring an additional 54,456 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Bio-Rad Laboratories during the 2nd quarter valued at about $17,690,000. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Bio-Rad Laboratories

In other news, COO Jonathan P. Divincenzo sold 919 shares of the business’s stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $390.47, for a total transaction of $358,841.93. Following the completion of the sale, the chief operating officer owned 1,962 shares in the company, valued at approximately $766,102.14. The trade was a 31.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Courtney C. Enloe sold 902 shares of the business’s stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $386.17, for a total value of $348,325.34. Following the sale, the executive vice president owned 750 shares of the company’s stock, valued at $289,627.50. The trade was a 54.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,221 shares of company stock worth $1,247,049 in the last three months. 30.34% of the stock is currently owned by company insiders.

Bio-Rad Laboratories Trading Down 1.0%

Shares of BIO traded down $3.88 during trading hours on Friday, hitting $366.60. The stock had a trading volume of 256,208 shares, compared to its average volume of 253,905. Bio-Rad Laboratories, Inc. has a 12-month low of $236.73 and a 12-month high of $396.23. The firm has a market cap of $9.86 billion, a P/E ratio of 9.65 and a beta of 1.06. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.37 and a current ratio of 3.18. The company’s fifty day simple moving average is $373.01 and its 200 day simple moving average is $317.45.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings results on Wednesday, November 4th. The medical research company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.23 by $0.42. Bio-Rad Laboratories had a return on equity of 3.58% and a net margin of 39.45%. The firm had revenue of $656.40 million during the quarter, compared to the consensus estimate of $649.94 million. During the same quarter in the previous year, the business earned $2.26 earnings per share. The firm’s quarterly revenue was up .5% compared to the same quarter last year. Equities research analysts forecast that Bio-Rad Laboratories, Inc. will post 9.71 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of Bio-Rad Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Citigroup boosted their target price on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Royal Bank Of Canada upped their price target on shares of Bio-Rad Laboratories from $390.00 to $440.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Finally, Wells Fargo & Company increased their price target on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Hold” and an average target price of $366.67.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc. develops, manufactures, and markets products used in life science research and clinical diagnostics. Founded in 1952 by David and Alice Schwartz, the company is headquartered in Hercules, California, and serves customers around the world. Through its Life Science segment, Bio-Rad supplies instruments, reagents, and software for areas including cell biology, genomics, protein analysis, and drug discovery. Its products support research at academic institutions, biotechnology and pharmaceutical companies, and other laboratories.